Foghorn Therapeutics, Inc.

How big is Foghorn Therapeutics, Inc.?

As of Jun 18, Foghorn Therapeutics, Inc. has a market capitalization of 267.00 million and reported net sales of 23.51 million with a net profit of -80.43 million over the last four quarters. Shareholder's funds are at -45.53 million, and total assets amount to 458.37 million.

As of Jun 18, Foghorn Therapeutics, Inc. has a market capitalization of 267.00 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 23.51 million, while the sum of net profit for the same period is -80.43 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at -45.53 million, and the total assets amount to 458.37 million.

What does Foghorn Therapeutics, Inc. do?

Foghorn Therapeutics, Inc. develops medicines targeting genetic dependencies in the chromatin regulatory system, with a market cap of $267 million and recent net sales of $6 million but a net loss of $19 million. The company operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap firm.

Overview: <BR>Foghorn Therapeutics, Inc. is focused on the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 6 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -19 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 267.00 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 3.43 <BR>Return on Equity: 126.58% <BR>Price to Book: -4.33<BR><BR>Contact Details: <BR>Address: 500 Technology Square, Suite 700, CAMBRIDGE MA: 02139 <BR>Tel: 1 617 5863100 <BR>Fax: 1 302 6555049 <BR>Website: http://foghorntx.com/

Should I buy, sell or hold Foghorn Therapeutics, Inc.?

Who are in the management team of Foghorn Therapeutics, Inc.?

As of March 2022, the management team of Foghorn Therapeutics, Inc. includes Mr. Douglas Cole as Chairman of the Board and founder, and Mr. Adrian Gottschalk as President, CEO, and Director.

As of March 2022, the management team of Foghorn Therapeutics, Inc. includes Mr. Douglas Cole, who serves as the Chairman of the Board and is also a founder of the company. Additionally, Mr. Adrian Gottschalk holds the positions of President, Chief Executive Officer, and Director.

Is Foghorn Therapeutics, Inc. overvalued or undervalued?

As of March 10, 2022, Foghorn Therapeutics, Inc. is considered a risky investment due to its negative valuation ratios and overvaluation compared to peers, with a current price of 5.14.

As of 10 March 2022, the valuation grade for Foghorn Therapeutics, Inc. has moved from does not qualify to risky. The company appears to be overvalued given its negative valuation ratios, including a P/E ratio of -4.31, an EV to EBITDA of -0.40, and an EV to Sales of 1.58. In comparison to peers, Poseida Therapeutics, Inc. has a P/E ratio of -15.24, while Verastem, Inc. shows a P/E of -4.03, indicating that Foghorn's valuation is relatively high among its risky peers.<BR><BR>The lack of positive valuation metrics, along with the company's current price of 5.14, suggests that it is overvalued in the current market context. Although specific return data is not available for comparison against the S&P 500, the overall risk profile and negative ratios reinforce the notion that Foghorn Therapeutics is not a favorable investment at this time.

Is Foghorn Therapeutics, Inc. technically bullish or bearish?

As of August 15, 2025, Foghorn Therapeutics shows a mildly bullish technical trend, supported by positive weekly and monthly MACD indicators, despite mixed signals from Bollinger Bands and underperformance compared to the S&P 500 over the past one to three years.

As of 15 August 2025, the technical trend for Foghorn Therapeutics, Inc. has changed from mildly bearish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish, indicating positive momentum. The daily moving averages also reflect a mildly bullish stance. However, the Bollinger Bands show a mixed signal with weekly mildly bullish and monthly mildly bearish readings. The KST is bullish on a weekly basis but bearish monthly, and the Dow Theory indicates a mildly bullish trend weekly but mildly bearish monthly. The OBV is mildly bearish across both time frames.<BR><BR>In terms of performance, Foghorn has underperformed the S&P 500 over the past year and three years, with returns of -46.23% and -40.23% respectively, compared to the S&P's 17.14% and 70.41%. Overall, the current technical stance is mildly bullish, but the strength is tempered by mixed signals from various indicators.